

The logo features a stylized liver shape in shades of orange and brown with a hexagonal pattern. The text '1st GLOBAL LIVER HEALTH FORUM' is written in white, bold, sans-serif font over the liver shape.

**1st GLOBAL
LIVER
HEALTH
FORUM**

SCIENCE TO ADVANCE LIVER HEALTH

October 23rd & 24th 2020

Virtual Forum

SANOFI 

The logo features a stylized, irregular shape with a honeycomb or hexagonal pattern, transitioning from a dark orange at the top to a lighter orange at the bottom. The text is white and positioned on the left side of this shape.

**1st GLOBAL
LIVER
HEALTH
FORUM**

SUMMARY



Welcome Letter	4
Agenda.....	5

SPEAKERS BIOGRAPHIES

Prof Zobair M. Younossi	6
Prof Jörn M. Schattenberg	7
Prof Marek Hartleb	8
Prof Chavdar Pavlov	9
Prof Huiying Rao	10
Prof Jian-Gao Fan	11
Prof Bogusław Okopień	12
Dr Asad Izziddin Dajani	13



WELCOME LETTER

Dear Participant,

It's a real honor to welcome you to our **1st Global Liver Health Forum**. In this 1st event, we aim to raise awareness about the burden of NAFLD, its early detection and optimal treatment. However, our enduring goal remains to provide an environment where the principal players in the field can directly share their insights and priorities in the area of liver diseases.

In this extraordinary environment of a world-wide pandemic that has so dramatically altered the way we live and work, we have decided to hold this forum as a virtual event, only. Thanks to the latest in streaming technology, you and your colleagues from all over the world will be able to attend the forum from where you are, and follow the sessions, and interact at the same time.

We are happy to provide a platform that will provide attendees the opportunity to engage, network, and collaborate with world renowned scientific experts. Our aim is to foster the exchange of creative ideas while creating long-lasting relationships to build a thriving, international community. We are sure that you, along with your peers from all over the world will be able to enjoy a productive and meaningful learning experience.

Finally, we would like to express our deep appreciation for the many individuals who made this Forum possible. We are particularly grateful to our speakers for sharing their passion, expertise and unique perspectives to create this unforgettable experience.

Yours sincerely,

Petra Kammann
Global Head Digestive Health,
Nutritionals & Claims

Branko Popovic
Global Medical Lead
Digestive Health

AGENDA



DAY 1: Friday, 23rd October 2020

TIME CET (UTC+2)	TOPICS	SPEAKER
14:00 – 14:15	Welcome and Introduction	Sanofi
14:15 – 14:40	Insights into NAFLD burden and epidemiology. What does the data tell us? Global insights	Prof Zobair M. Younossi
14:40 – 15:05	NAFLD and metabolic comorbidities. Current understanding and perspectives	Prof Jörn M. Schattenberg
15:05 – 15:15	Q&A Session 1	
15:15 – 15:45	Break	
15:45 – 16:10	Therapeutic approaches for NAFLD	Prof Marek Hartleb
16:10 – 16:35	Importance of RWE in understanding the current disease landscape: MANPOWER results put into perspective	Prof Chavdar Pavlov
16:35 – 16:45	Q&A Session 2	
16:45 – 17:00	Conclusions and closing remarks	Sanofi

DAY 2: Saturday, 24th October 2020

TIME CET (UTC+2)	TOPICS	SPEAKER
10:00 – 10:15	Welcome and Introduction	Sanofi
10:15 – 10:40	What does a NAFLD patient journey look like? Importance of HR-QoL	Prof Huiying Rao
10:40 – 11:05	Emerging role of hepatoprotective treatment options	Prof Jian-Gao Fan
11:05 – 11:30	Essential phospholipids. Mechanism of action in liver disease explained	Prof Bogustaw Okopień
11:30 – 11:40	Q&A Session 3	
11:40 – 12:10	Break	
12:10 – 12:35	The role of the essential phospholipids in the NAFLD continuum	Dr Asad Izziddin Dajani
12:35 – 13:00	Panel discussion (including 10 minutes for Q&A session 4)	
13:00 – 13:15	Conclusions and closing remarks	



Prof Zobair M. Younossi

President of Inova Medicine, Inova Health System and the Chairman and Professor of Medicine, Inova Fairfax Medical Campus.

Prof Younossi is the President of Inova Medicine, Inova Health System and the Chairman and Professor of Medicine, Inova Fairfax Medical Campus. He is also the Chairman of Clinical Research, Inova Health System.

Prof Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, New York (Alpha Omega Alpha, 1989), and completed his residency in internal medicine as well as a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California. During his residency and fellowship, he earned his Master of Public Health degree from San Diego State University (SDSU) School of Public Health in San Diego, California, being awarded both the Hanlon Award and Outstanding Student Award for SDSU. He then served as the Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio (1995– 2000). In 2000, Prof Younossi joined Inova Health System to establish the Center for Liver Diseases.

Prof Younossi is an internationally known hepatologist who has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes, economic assessment and outcomes research in liver disease. He is the Chair of Global NASH Council and the Global Liver and NASH Registries. His research in both NAFLD and outcomes research is extensively cited and he is a highly sought-after speaker for national and international scientific meetings. Prof Younossi specializes in hepatology and gastroenterology and has authored over 600 articles, 3 books, 6 journal supplements and has delivered over 430 faculty lectures in national and international meetings. Prof Younossi has also served as the co-editor of Liver International, Associate Editor of Journal of Hepatology and the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

Insights into NAFLD burden and epidemiology. What does the data tell us? Global insights

What you will learn:

Burden of NAFLD and how we can interpret the available data:

- Worldwide prevalence of NAFLD is very high particularly amongst people with diabetes.
- Increasing number of NAFLD patients are progressing to NASH.
- NAFLD is now the most frequent cause of liver disease worldwide and NASH is the potentially progressive type of NAFLD.
- The high burden of NASH will have important clinical and economic consequences.



Prof Jörn M. Schattenberg

Director of the Metabolic Liver Research Program, University Medical Center Mainz, Germany.

Prof Schattenberg is the Director of the Metabolic Liver Research Program and the Clinical Liver Research Unit at the University Medical Center Mainz, Germany. He is a full professor of Medicine and serves on the Editorial Board of Hepatology and Alimentary Pharmacology & Therapeutics. He is a member of the executive committee of the LITMUS consortium for the validation of biomarkers in NASH. His research interests are on clinical and experimental aspects of metabolic and toxic liver injury, the development of therapeutic intervention and novel biomarkers in NASH.

NAFLD and metabolic comorbidities. Current understanding and perspectives

What you will learn:

The multifactorial, progressive aspects of fatty liver disease:

- NAFLD and NASH are widespread worldwide.
- There is interaction between the liver and other organs in the context of metabolic disease.
- There is a higher risk of mortality when greater fibrosis is present.
- Metabolic comorbidities represent important risk factors for the development and prognosis of NAFLD.
- Differences between patients could be harnessed to provide more targeted, personalized treatments for better outcomes.



Prof Marek Hartleb

Head of the Gastroenterology and Hepatology Department at the Medical University of Silesia in Katowice and member of the Main Board of the Polish Gastroenterological Society (PTG-E).

Prof Hartleb is the Head of the Gastroenterology and Hepatology Department at the Medical University of Silesia in Katowice. He is also member of the Main Board of the Polish Gastroenterological Society (PTG-E) and Head of Expert Group of NAFLD Section of PTG-E. Prof Hartleb is currently Chairman of the Faculty's Scientific Committee, as well as a member of the Scientific Council for the following magazines: Gastroenterological Review, Medical News, Post-Diploma Medicine, World Journal of Gastroenterology and NA Rescue. His research interest is nonalcoholic and fatty liver diseases.

Therapeutic approaches for NAFLD

What you will learn:

- Dietary and lifestyle changes are advised to control NAFLD often with no other treatment.
- Therapeutic approaches used in NAFLD are normally directed towards the existing comorbidities such as dyslipidemia, hypertension, diabetes.
- The importance of treating NASH with liver-directed therapies when so few are currently available due to insufficient evidence of efficacy or unfavourable safety profiles.
- Discuss the drugs which are currently in Phase 3 trials to treat NASH.



Prof Chavdar Pavlov

Head of the Department of Therapy and Head of the Center for evidence based medicine, 'Sechenov' First Moscow State Medical University.

Prof Pavlov is Head of the Department of Therapy and Head of the Center for Evidence-Based Medicine at 'Sechenov' First Moscow State Medical University, Russia. He is also editor for Cochrane Hepato-Biliary Group, providing guidance to authors and ensuring the quality of their work. Prof Pavlov is Vice President for foreign relations with the Russian Scientific Liver Society and Vice President of the Russian Scientific Society for the Study of Microbioma. His research interests are fatty liver diseases.

Importance of RWE in understanding the current disease landscape: MANPOWER results put into perspective

What you will learn:

The main findings from the large real-world study of newly diagnosed NALFD patients, MANPOWER:

- The typical patient profile, age, sex, comorbidities and current treatments.
- The symptoms of patients newly diagnosed with NAFLD.
- Six-month follow-up of symptoms such as steatosis, liver function tests and dyslipidemia with adjuvant EPLs.
- The good compliance to adjuvant EPL therapy.



Prof Huiying Rao

Chief physician, professor, and assistant director of Peking University Hepatology Institute. She is also deputy director of the scientific research department and deputy director of the clinical trial institution in Peking University People's Hospital.

Prof Rao is the Chief physician and professor, and assistant director of Peking University Hepatology Institute, China. She is also the deputy director of the scientific research department and deputy director of clinical trial institution in Peking University People's Hospital, China.

Prof Rao carried out her medical and research training at Peking University Health Science Center before being appointed as lecturer in infectious diseases in 2006. Her research interests are in clinical management of viral hepatitis, fatty liver diseases and cirrhosis.

What does a NAFLD patient journey look like? Importance of HR-QoL

What you will learn:

What is the NAFLD patient journey in China:

- There is poor awareness of NAFLD in China.
- NAFLD has a detrimental effect on patients' quality of life, with significant negative associations between HR-QoL and clinical factors including BMI, disease severity, cardiovascular disease etc.
- A large multi-centre study which has identified areas we need to improve in the care of these patients regarding HR-QoL.



Prof Jian-Gao Fan

Professor and Director of the Center for Fatty Liver and the Department of Gastroenterology at Xinhua Hospital, China. Principle Investigator of the Shanghai Key Lab of Pediatric Gastroenterology and Nutrition.

Prof Fan is Professor and Director of the Center for Fatty Liver and the Department of Gastroenterology at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, China. He is also the Principle Investigator of the Shanghai Key Lab of Pediatric Gastroenterology and Nutrition as well as Editor-in-Chief of the Chinese Journal of Practical Hepatology. Prof Fan is a member of the editorial board of more than 20 journals and he is also a peer-reviewer for many other major journals. His activities include clinical care, research and teaching of Gastroenterology and Hepatology. His main research interests are in the fields of metabolic syndrome and chronic liver diseases.

Emerging role of hepatoprotective treatment options

What you will learn:

NAFLD is characterized by steatosis related to over-nutrition and insulin resistance:

- Lifestyle modifications can be effective; however, they are difficult to achieve and sustain.
- The term 'metabolic associated fatty liver disease' (MAFLD) has been proposed as an alternative nomenclature to NAFLD, and this redefinition may allow for sub-stratifying of patient phenotype.



Prof Bogusław Okopień

Head of the Department of Internal Medicine and Clinical Pharmacology at the Medical University of Silesia and Medical Director at NZOZ Terapia Optima in Katowice.

Prof Okopień is Head of the Department of Internal Medicine and Clinical Pharmacology at the Medical University of Silesia and Medical Director at NZOZ Terapia Optima in Katowice, Poland. Prof Okopień has achieved specializations in Internal Medicine, Clinical Pharmacology and Hypertensiology. He is a member of the Polish Pharmacological Society, Polish Society of Clinical Pharmacology & Therapy, Polish Society of Internal Medicine, Society of Monitored Therapy, New York Academy of Sciences, Polish Society of Insurance Medicine, Polish Society for the Research of Atherosclerosis, and the International Atherosclerosis Society. Prof Okopień has received a medal for the National Education Committee, the 100th Anniversary of the Polish Society of Internal Medicine and the Badge of Merit for the Silesian Medical University.

He is the author of 587 scientific papers and his main research interest is in the field of pharmacology, where his team have received several awards: the 1st degree of the Minister of Health twice; the 2nd degree award of the Rector of ŚAM; and the 1st degree Rector of SUM.

Essential phospholipids. Mechanism of action in liver disease explained

What you will learn:

The mechanism of action of essential phospholipids (EPLs) in liver disease. EPLs exert a triple activity in liver diseases:

- Active regeneration of liver cells.
- Detoxification of the liver.
- Protective effect on hepatocytes.
- These mechanisms explain the beneficial clinical effects seen when EPLs are used as adjuvant therapy in NAFLD and NASH.



Dr Asad Izziddin Dajani

Consultant Gastroenterologist & Hepatologist at Asad Dajani Specialized Clinic, with affiliation to Medcare and Saudi German hospital in Sharjah.

Dr Dajani is a Consultant Gastroenterologist & Hepatologist at Asad Dajani Specialized Clinic, with affiliation to Medcare and Saudi German hospital in Sharjah, United Arab Emirates. He was instrumental in establishing the Endoscopy service at the Kuwait and Al Qassimi Hospitals in Sharjah, United Arab Emirates.

Dr Dajani has many publications in the field of his work and is also member of the editorial board of many reputed Journals of Gastroenterology and chairman and moderator for many of the local Emirates Medical Associations, regional and international symposia and conferences.

The role of the essential phospholipids in the NAFLD continuum

What you will learn:

The importance of essential phospholipids as an adjuvant treatment in NAFLD, showing:

- Reliable data from clinical trials.
- Recent results from a large real-life study.
- The marked histopathological improvements seen with EPLs.
- The effects of EPLs at different stages of the NAFLD continuum.

**1st GLOBAL
LIVER
HEALTH
FORUM**

SANOFI 

MAT-GLB-2002319